← Back to Search

CFTR Modulator

Lung Perfusion Mapping for Cystic Fibrosis

Phase 4

Waitlist Available

Led By Mark DiFrancesco, PhD

Research Sponsored by Children's Hospital Medical Center, Cincinnati

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Inclusion CF Cohort: diagnosis of CF by positive sweat test and genetic test

Inclusion CF Cohort: Absence of exacerbation defined as O2 saturation level at 90% or greater when laying flat

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 6 months post trikafta initiation for cf group. baseline for cf and control groups.

Awards & highlights

Drug Has Already Been Approved

No Placebo-Only Group

Pivotal Trial

Summary

This trial will use a new MRI method to measure regional lung perfusion in children with CF and relate it to regional assessments of ventilation and to serum cytokines or proteomic markers of angiogenesis and inflammatory processes.

Who is the study for?

This trial is for children and young adults aged 6-21 with cystic fibrosis (CF) confirmed by tests, who are about to start Trikafta treatment. Healthy individuals of the same age without lung issues can also join as controls. Participants need stable lung function and no recent exacerbations or antibiotic treatments.

What is being tested?

The study tests a new MRI technique that maps blood flow in the lungs without contrast agents, alongside hyperpolarized Xenon to map ventilation. It aims to understand how CF affects lung perfusion and its relationship with ventilation defects over time.

What are the potential side effects?

Since this trial involves non-invasive imaging techniques rather than drugs, side effects may be minimal but could include discomfort from lying still during MRI scans or mild anxiety due to claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with cystic fibrosis through a sweat and genetic test.

Select...

My oxygen levels stay above 90% when I'm lying down.

Select...

I am between 6 and 21 years old and healthy.

Select...

My lung function is within 5% of my best result in the past 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 6 months post trikafta initiation for cf group. baseline for cf and control groups.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 6 months post trikafta initiation for cf group. baseline for cf and control groups.

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 months post trikafta initiation for cf group. baseline for cf and control groups. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Degree of concordance between ventilation and perfusion defects

Perfusion Defect Percentage (PDP)

Proteome assays as global indicators of inflammatory/angiogenic processes

+1 more

Awards & Highlights

Drug Has Already Been Approved

The FDA has already approved this drug, and is just seeking more data.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Control CohortExperimental Treatment1 Intervention

10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.

Group II: CF CohortExperimental Treatment2 Interventions

16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.

0 / 4Eligibility criteria met